Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polybrene (hexadimethrine bromide) is a cationic polymer primarily utilized as a research reagent to enhance the efficiency of viral transduction into mammalian cells by neutralizing the charge repulsion between the viral particles and the cell membrane. Historically, it was employed clinically as a heparin antagonist to reverse anticoagulation, although it has largely been superseded by protamine sulfate due to toxicity concerns. Emerging research, particularly in neuro-oncology, has identified polybrene as a potential tool for glioblastoma subtyping. It demonstrates selective cytotoxicity against neural progenitor-like (NPC-like) glioblastoma cells by activating calcineurin (a calcium/calmodulin-dependent serine/threonine protein phosphatase), while mesenchymal-like (MES-like) cells remain resistant. This property allows for a rapid and cost-effective method to profile tumor heterogeneity and potentially inform personalized therapeutic strategies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hexadimethrine bromide.